A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery

Trial Profile

A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Becatecarin (Primary) ; Fluorouracil; Folic acid
  • Indications Biliary cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Exelixis; Helsinn
  • Most Recent Events

    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004071).
    • 13 Jan 2009 Added actual trial completion date, as reported by ClinicalTrials.gov.
    • 21 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top